It seems obvious that the nervous system is composed of many distinct components. The anatomical differences between neurons was known by 1900, but it took additional time before advances in molecular biology gave us techniques that rivaled the power of the Golgi method. Hybridoma technology was the first of these new methods to teach us that molecular differences between neurons are fundamental to the way the brain works (Zipser and McKay 1981) . The sheer scale of the molecular diversity of the brain made the origin of these differences a compelling question. The first evidence for multipotent neural precursors in the central nervous system (CNS) was reported many decades ago (Nieuwkoop 1973; Ready et al. 1976 ). On the basis of this pioneering work, we established tools to identify and manipulate these cells. Neural precursors in the developing brain were first identified by a specific monoclonal antibody (Hockfield and McKay 1985; Frederiksen and McKay 1988) . The antibody recognized an intermediate filament protein whose precise expression pattern is regulated by a conserved enhancer that directs gene expression to neural precursors (Lendahl et al. 1990; Zimmerman et al. 1994) . These powerful regulatory elements in the nestin gene are now widely used to achieve specific genetic manipulation of the brain (Josephson et al. 1998; Lonigro et al. 2001; Tanaka et al. 2004 ). The initial identification of precursor cells in vivo was followed by evidence that proliferating nestin-positive cells would generate functional neurons in vitro and that these cells would incorporate into the brain (Cattaneo and McKay 1990; Renfranz et al. 1991; Vicario-Abejón et al. 1995 . These experiments opened up the idea that large numbers of functional neurons could be generated in the laboratory.
Controlling the ex vivo production of neurons has become a widely pursued activity often justified as the basis for new cell therapies for degenerative disease. Transplants of fetal mesencephalic tissue into the striatum of patients with Parkinson's disease (PD) suggest that cell replacement therapies may be beneficial. The grafted neurons can reinnervate the diseased brain and restore function, but problems limit this approach, including the scarcity of tissue suitable for transplantation (Lindvall and Björklund 2004) . Stem cell technologies may provide large numbers of dopamine neurons that are specifically required for PD cell therapy. The most obvious source of these cells is the fetal midbrain that normally generates dopamine neurons during development. Midbrain precursors can divide in vitro and then differentiate into dopamine neurons, but the short proliferative phase limits the numbers of neurons that can be generated (Studer et al. 1998) . We now know that dopamine neurons are derived from the midbrain floor plate, a region of the brain not previously thought to generate neurons (Kittappa et al. 2007 ). Distinct mechanisms may control proliferation of floor-plate precursors, but whatever the case, this limitation was overcome by deriving dopamine neurons from embryonic stem (ES) cells.
Some years after ES cells were first obtained, they were shown to incorporate into the inner cell mass of the blastocyst and generate chimeras with donor cells in all tissues including the germ line (Bradley et al. 1984; Thomas and Capecchi 1986) . These results showed that ES cells were pluripotent, but it took additional experiments to demonstrate efficient production of somatic fates in vitro. Using our knowledge of neural precursors to optimize the differentiation protocol, we showed that neurons could be generated as efficiently from ES cells as from the developing brain (Okabe et al. 1996) . This remarkable result led to further studies showing that ES-derived oligodendrocytes would myelinate axons in a model of human demyelinating disease (Brüstle et al. 1999) . It is a measure of the enthusiasm for these ideas that oligodendrocytes derived by in vitro methods from human ES cells may soon be used in clinical trials (Keirstead et al. 2005) . Endodermal fates can also be derived from ES cells. Induced insulin secretion, plasma glucose regulation, and weight control suggest that ES-derived cells conduct pan-
Signaling Pathways Controlling Neural Stem Cells Slow Progressive Brain Disease
The identification and characterization of multipotent neural precursors open the possibility of transplant therapies, but this approach is complicated by the widespread pathology of many degenerative diseases. Activation of endogenous precursors that support regenerative mechanisms is a possible alternative. We have previously shown that Notch ligands promote stem cell survival in vitro. Here, we show that there is an intimate interaction between insulin and Notch receptor signaling. Notch ligands also expand stem cell numbers in vivo with correlated benefits in brain ischemia. We now show that insulin promotes recovery of injured dopamine neurons in the adult brain. This response suggests that activating survival mechanisms in neural stem cells will promote recovery from progressive degenerative disease.
creatic endocrine functions (Lumelsky et al. 2001; Shim et al. 2007) . Electrophysiological measurements, dopamine release, positron emission tomography (PET) chemistry, and behavioral responses show that functional dopamine neurons can be derived from ES cells (Kim et al. 2002; Rodríguez-Gómez et al. 2007 ). These grafting studies provide some of the clearest examples supporting the worldwide interest in using human pluripotent cells. Despite this success, major difficulties inhibit implementing cell therapy for neurodegenerative disease. The intermediate steps between pluripotent precursors and mature functional neurons are still being defined (Tesar et al. 2007; Elkabetz et al. 2008) . Even when we have solved the logistically complex task of generating consistently high-quality donor cells, a successful cell therapy will still demand strong knowledge of disease mechanisms. In PD, pathological evidence suggests that the deficits involve many neurons other than dopamine neurons (Braak and Del Tredici 2008) . There is increasing evidence that widely disseminated pathology leads to the death of striatal medium spiny neurons in Huntington's disease (HD) and motor neurons in amytotrophic lateral sclerosis (ALS) and in the spinocerebellar atrophies (SCA) (Zuccato et al. 2001; Orr and Zoghbi 2007; Yamanaka et al. 2008) . These insights into disease mechanisms raise concerns about the value of transplanting a specific neuron type in a degenerating brain where the disease may be initiated elsewhere and involve many other neuron types. Here, we suggest a different approach where injured neurons are not replaced but restored to health by treatments that stimulate endogenous precursors in large regions of the brain.
It might be valuable to consider for a moment what it takes to keep a cell alive. In 1890, embryology was a flourishing enterprise at Woods Hole where Thomas Hunt Morgan worked a few years after his graduation from Johns Hopkins University. In that same summer, Ross Harrison who was an undergraduate at Johns Hopkins also worked at Woods Hole. Ross Harrison showed that axons would grow out when brain explants were placed in a drop of clotted frog lymph. Subsequently, the technology for growing cells in culture was extended. HeLa cells were placed in culture in 1930, again at Johns Hopkins. Although neurons were among the first cells to be studied in cell culture, the clear demonstration that neurons could be derived from precursors that had expanded in the laboratory is surprisingly recent and depended on using defined growth factors (Barnes and Sato 1980) . Access to pure growth factors became possible as techniques for cloning and expressing genes were commercialized. In Europe and America in 1982, insulin became the first recombinant protein approved for clinical use. Access to insulin and fibroblast growth factor-2 (FGF-2) allowed the first definitive demonstration that proliferating precursors would transform into neurons in cell culture (Cattaneo and McKay 1990) .
In neural stem cells, we made the surprising observation that ligands for the Notch receptor also control cell survival through a transient activation of phosphoinositol-3 kinase (PI3K) Akt (Androutsellis- Theotokis et al. 2006) . Notch encodes a trans-membrane receptor that is cleaved on activation to release an intracellular domain that is directly involved in transcriptional control and regulates
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cell fate (Heitzler and Simpson 1991; Ruohola et al. 1991; Greenwald and Rubin 1992; Spana and Doe 1996; Artavanis-Tsakonas et al. 1999) . Transcriptional regulation has been the primary focus of contemporary Notch research. The mechanism that transfers information from the surface receptor to the nucleus was clarified when it was demonstrated that the Notch protein was cleaved and the intracellular domain was itself a transcriptional regulator (Kidd et al. 1986; Blaumueller et al. 1997) . A detailed model is now available for the interaction between the Notch intracellular domain (NICD) and other transcriptional cofactors (Wallberg et al. 2002; Nam et al. 2006; Yoshimatsu et al. 2006 ). The Notch receptor and ligands are expressed in the developing vertebrate CNS where gain-and loss-of-function experiments show that Notch inhibits the cascade of events required for the formation of neurons and promotes the differentiation of glia (Morrison et al. 2000; Tanigaki et al. 2001) . In mice, the two homologs of the Drosophila Notch inhibitor numb are required for the maintenance of the neural precursor state in the developing and adult nervous system (Kuo et al. 2006) .
In culture, the homogeneity of cells derived from the fetal telencephalon makes them ideal for signal transduction studies. Importantly, they can be grown in serum-free medium containing only three exogenous proteins: apotransferrin for iron transport, FGF-2, and insulin. Under these conditions, a proportion of the cells die. This death is abruptly blocked by soluble ligands that activate the Notch receptor, including Deltalike-4 (Dll4) and Jagged (Jag). The novel survival effect of Notch ligands involves many components of the phosphorylation cascade associated with surface trysoine kinase receptors (Androutsellis- Theotokis et al. 2006) .
INSULIN AND DLL4 COOPERATE TO PROMOTE DOWNSTREAM SIGNALING
Neuroepithelial cells express both insulin-like growth factor-1R (IGF-1R) and Notch1, and their survival is sensitive to both the γ-secretase and PI3K inhibitors. The insulin superfamily contains insulin, IGF-1 and IGF-2, and the relaxins (INSL3-7). These growth factors bind to multiple receptors, but the activation of receptor tyrosine kinases dominates our current thinking on the cellular response to insulin and IGFs. There are about 60 receptor tyrosine kinases in the human genome and there is great interest in the molecular mechanisms that activate them (Weiss and Schlessinger 1998) . Both IGFs act through the IGF-1R, and there is compelling evidence that IGF-2 controls cell survival during mouse development (Burns and Hassan 2001) . IGF-1R activates an intracellular signaling cascade that includes acute increases in the phosphorylation of the PI3K and Akt kinases and this leads glucose uptake and cell survival (Dudek et al. 1997; Stokoe et al. 1997) .
This idea that cell survival is mediated by both Notch and IGF-1R led us to investigate the interaction of Delta4 and insulin on receptor activation. Western blots with an antibody that recognizes the phosphorylated IGF-1R show that Dll4 induces receptor activation (Fig. 1a) . The signal from insulin treatment is also shown (Fig. 1a, inset ). In the absence of insulin, Dll4 still stimulates rapid phosphorylation of both major activating sites on Akt (Fig. 1b) . The phosphorylation of IGF-1R in response to Dll4 may explain the Akt activation.
In a further experiment, the effect of insulin on the level of the cleaved intracellular fragment of the Notch (NICD) protein was assessed. Neural stem cells (NSCs) were maintained for 16 hours without insulin and western blots were performed 1 hour after treating the cells (Fig. 1c) . Addition of insulin gave strong phosphorylation of the IGF-1R. Consistent with the brief IGF-1R response to Dll4, no increase in activated IGF-1R was observed 1 hour after Dll4 treatment. Our previous report on the Notch survival pathway showed that a 1-hour treatment with Dll4 generates elevated levels of the NICD in the presence of insulin, but this was not observed in the absence of insulin (Fig. 1c) . However, insulin treatment caused elevated levels of NICD and this was sensitive to γ-secretase inhibition. The reduced activation of IGF-1R in the presence of DAPT, the synergy between insulin and Dll4 on NICD levels, and the γ-secretase-dependent elevation of NICD by insulin all support a link between these two signals.
Following Dll4 treatment, NSCs show an activation of a serine residue (Ser-727) on STAT3 (signal tranducer and activator of transcription 3) that is required for cell survival (Androutsellis-Theotokis et al. 2006) . The action of JAK tyrosine kinases on Tyr-705 is considered to be the major regulator of STAT3 nuclear translocation and transcriptional activation (Levy and Darnell 2002) . Elevated GFAP (glial fibrillary acidic protein) expression and astrocyte differentiation are seen when neural stem cells are treated with growth factors that induce JAK activity (Johe et al. 1996; Bonni et al. 1997) . Undifferentiated NSCs show very low levels of Tyr-705 phosphorylation, and Ser-727 phosphorylation occurs after insulin treatment (Fig. 1d) . This result shows that insulin and Notch activation have similar effects on this key downstream component of the signaling cascade that controls stem cell survival.
INSULIN AND DLL4 ACT THROUGH HES3 TO PROMOTE STEM CELL SURVIVAL
The effects of insulin and Dll4 on the survival of fetal and adult NSCs were assessed. Insulin and Dll4 alone promote the expansion of fetal mouse telencephalic cells in culture, but their effect is greater when combined (Fig. 2a) . The concentration of insulin used far exceeds the halfmaximal concentration for receptor phosphorylation, and dose-response curves for Dll4 also suggest that saturating levels of the ligand are present. The subventricular zone (SVZ) of the adult rat telencephalon unusually contains large numbers of precursor cells that generate proliferating cellular aggregates known as neurospheres (Reynolds and Weiss 1992; Luskin 1993; Doetsch and Alvarez-Buylla 1996) . Here, we show that insulin and Dll4 allow the direct isolation of highly enriched proliferating precursors when cells from the SVZ of the adult rat brain are dissociated and placed in attached culture (Fig. 2b) .
Nuclear translocation of the NICD leads to the transcriptional regulation of Hes and Hey target genes. In the fetal brain, Hes1, 3, and 5 act cooperatively to sustain the neuroepithelial compartment (Hatakeyama et al. 2004 ). The survival signaling pathway downstream from Dll4 leads to a rapid and specific increase in mRNA for the Hes3 gene (Androutsellis- Theotokis et al. 2006) . Here, we show that Hes3 is required for the survival of precursors from the adult SVZ in response to either insulin or Dll4 (Fig. 2c) . This result strongly supports a critical role for this new signaling pathway in survival responses of adult stem cells to insulin.
INSULIN PROTECTS DOPAMINE NEURONS FROM 6-OHDA TOXICITY
As a consequence of the aging population, there are growing concerns about the financial and social costs of neurodegenerative disease. Growth factors that stimulate the recovery of the injured brain have been pursued since Rita Levi-Montalcini made the observation of excess neuronal survival that led to the isolation of nerve growth factor (NGF) (Levi-Montalcini 1987) . In the case of the degeneration of dopamine neurons seen in PD, new therapies using growth factors in the glial-cell-derived neurotrophic factor (GDNF) family are being pursued most avidly. This enthusiasm is based on the initial identification of GDNF as a survival factor for midbrain dopamine neurons in cell culture and the subsequent demonstration that lentiviral delivery of GDNF rescued injured midbrain dopamine neurons in primates (Kordower et al. 2000) . The use of cytotoxic drugs currently provides the most widely used assay for developing therapies for PD. The specificity of these drugs takes advantage of the highaffinity systems that recover and recycle released dopamine. Dopamine neurons are specifically killed when the compound 6-hydroxy-dopamine is injected into the striatum of an adult rat (Przedborski et al. 1995) . The striatum contains the axonal projections of dopamine neurons with cell bodies located in the ventral midbrain. These cell bodies degenerate with a predictable time course in the 4-6 weeks following injection of the toxin.
Single injections of insulin 2 weeks after the cytotoxic lesion was administered conferred significant protection on dopamine neurons; 13 weeks after insulin treatment (i.e., 15 weeks after 6-OHDA lesion), the insulin-treated brains showed a greater tyrosine hydroxylase (TH, a marker of dopamine neurons) signal in the ipsilateral to lesion hemisphere (Fig. 3a) . When the retrogradely transported dye fluorogold was injected into the striatum ipsilateral to lesion 1 week before sacrifice, many TH + cell bodies were labeled in the insulin-treated animals (Fig.  3a) . This result demonstrates that the rescued neurons in the substantia nigra had intact processes that extended into the striatum. In addition, the rescued neurons had cell bodies that were significantly larger in size than controls (Fig. 3a) . This is in line with previous reports that the size of dopamine neuron bodies is a measure of their functional strength (Russo et al. 2007 ).
The behavioral impact of the rescued neurons was assessed by measuring the asymmetry in amphetamineinduced rotations. This assay is known to measure the deficit induced by the specific loss of dopamine neurons and is now widely used to monitor dopamine replacement or recovery (Dunnett et al. 1988) . In dopamine neurons derived from the fetal brain, expanded fetal precursors, or ES cells obtained through an enriching step, the behavioral recovery occurs rapidly (Dunnett et al. 1988; Studer et al. 1998; Kim et al. 2002) . A single insulin treatment induced a rapid reduction in the asymmetric rotations that stabilized after approximately 3 weeks and was sustained for a further 10 weeks (Fig. 3b) . These anatomical data and behavioral kinetics establish that insulin rescues dopamine neurons with intact and functional nigrostriatal connections.
CONCLUSIONS
As we noted earlier, the use of defined growth factors was critical to the first production of neurons in vitro and to the identification of multipotent neural stem cells. In more recent work, we showed that Notch ligands control survival of neural precursors, fetal pancreatic precursors, and human ES cells (Androutsellis-Theotokis et al. 2006 ). This was an exciting finding because it identified Notch, STAT3, and Hes3 as novel components of the signaling cascade that regulates the survival and growth of neural stem cells. The work we present here shows that all three proteins are intimately associated with survival signaling downstream from insulin. In neural stem cells, insulin has a more important influence on cell survival than does FGF-2. FGF-2 in contrast supports cell growth but does not have a major effect on survival (Rao et al. 2008) . The importance of insulin for the survival of vertebrate cells in culture was initially established empirically (Barnes and Sato 1980) . The interaction between receptor tyrosine kinases and Notch illustrates how access to stem cells can define fundamental new features of the signaling logic controlling cell survival.
Recent work shows that insulin acts directly to regulate synapse and circuit function in the Xenopus visual system (Chiu et al. 2008 ). In the rat striatum, loss of pancreatic insulin reduces striatal dopamine function, and this loss can be restored when insulin is directly injected into the brain (Williams et al. 2007 ). These results suggest that the insulin/IGF receptors are a physiologically important stimulus in the vertebrate CNS and more specifically in the striatum. In the case of PD, the family of ligands related to GDNF has received the most attention, but the most prominent receptor (RET) for these ligands is not required for the maintenance of adult neurons (Jain et al. 2006) . GDNF is normally synthesized by astrocytes, and recent studies developing a GDNF-based gene therapy suggests that expression in astrocytes has a better effect on dopamine neurons than expression in neurons (Do Thi et al. 2007 ). These results suggest that the neuroprotective responses of GDNF are indirect. Our data suggest that a general model that explains the survival of dopamine neurons must also include insulin and Notch receptors.
Although we focus on the relationship between stem cell survival and dopamine neurons in this chapter, it seems likely that these signaling pathways will have regenerative effects in other brain diseases and in other tissues. Two examples illustrate this point. Notch signaling controls muscle regeneration, and the efficacy of this process diminishes with age (Carlson et al. 2008) . IGF-1 has a powerful role in the recovery of muscle after injury (Mourkioti and Rosenthal 2005) . These results suggest that the Notch/IGF-1R system controls regeneration in many tissues.
Our data also show that these widely distributed prosurvival pathways can be readily activated by a single treatment. A simple strategy to activate a widely distributed prosurvival response has clear implications in medicine. Progressive degeneration of dopamine neurons occurs when humans are transiently exposed to a toxin that targets dopamine neurons (Langston et al. 1999) . It is clear that insulin is a well-characterized and widely available drug that should be considered as a treatment for such cases of acute toxicity, but might we use insulin/IGF/Notch signaling more widely in PD?
Our understanding of PD has been advanced by the identification of α-synuclein as a familial cause of the disease and a component of Lewy bodies, protein aggregates found in the injured brain (Polymeropoulos et al. 1997; Spillantini et al. 1997) . Postmortem histopathology, including analysis of Lewy bodies, shows that the major cortical, nigral, and local inputs to striatal neurons go STEM CELLS AND NEUROPROTECTION 407 Two weeks after the 6-OHDA lesion, animals were given a single intracerebroventricular injection (5 µl) with either artificial cerebrospinal fluid containing BSA (bovine serum albumin) (0.01%) as carrier (control) or insulin (8 mg/ml, in artificial cerebrospinal fluid containing 0.01% BSA). In control and insulin-treated animals, stereotaxic injections were placed into the right lateral ventricle using the following coordinates: bregma AP -0.9 mm, ML -1.4 mm, VD +3.8 mm; 12 weeks later, the rats were given a single injection of fluorogold in the ipsilateral to lesion and treatment striatum. One week after that, they were sacrificed and analyzed immunohistochemically. Relative to controls, insulin-treated brains showed a significantly increased TH signal in the striatum. Insulin-treated brains also had a greater number of TH + /fluorogold + cell bodies. These cell bodies were also larger in size. Antityrosine hydroxylase antibodies P80101 and P40101 were obtained from Pel-Freez. (b) Amphetamine-induced rotometry shows an improvement in the motor behavior of rats. Asymmetric movement in control rats increased for approximately 4 weeks until it stabilized. In contrast, insulin-treated rats improved for approximately 3 weeks and stabilized. Unilateral lesion of the nigrostriatal dopamine pathway was achieved by stereotaxic injection of 50 µg of 6-hydroxydopamine (6-OHDA) into the right striatum, using the following coordinates: bregma AP +0.5 mm, ML -3.0 mm, VD +5.5 mm. The behavioral analysis was performed as described by Kim et al. (2002) . Insulin (40 µg) was delivered as a single injection. Results shown are the mean ±S.D. or mean ±S.E.M. as indicated. Asterisks identify experimental groups that were significantly different (p value < 0.05) from control groups by the Student's t-test (Microsoft Excel), where applicable.
through a characteristic series of changes in PD (Braak and Del Tredici 2008) . These observations support a view that PD is a member of a wider group of diseases (Langston 2006) . The evidence that Notch ligands and insulin have regenerative effects in vivo supports their use to delay the age-dependent damage that is a cardinal feature of PD and other neurodegenerative diseases. The pathology stresses the need to develop treatments that stimulate widely dispersed prosurvival responses. The insulin/IGF/Notch pathway may meet this need. It is important to note that the proliferation of endogenous neural precursors declines when dopamine neurons are absent, suggesting that stem cell functions will be depressed in PD (Höglinger et al. 2004) . Mutually beneficial signals may pass between neural stem cells and dopamine neurons.
We have focused here on the role that endocrine hormones have in the survival of stem cells and adult dopamine neurons. We show that insulin and Notch receptors interact to control the signaling cascade that is fundamental to cell growth. In addition, we demonstrate pharmacological manipulation that promotes long-term recovery of dopamine neurons from injury. Recent work from our group also shows that the same core mechanism, involving the foxa2 gene, specifies the early generation and the late survival of dopamine neurons in old age (Kittappa et al. 2007 ). FoxA2 is a member of the foxo group of forkhead genes that are central mediators in cell survival. We have defined an FGF receptor, FGF-R1, expressed in the adult dopamine neurons at most risk in PD (van der Walt et al. 2004; Murase and McKay 2006) . These discoveries begin to define key cell-autonomous components of survival signaling that respond to the state of surrounding stem cells and astrocytes. A deeper understanding of how intrinsic and extrinsic factors interact to promote progressive positive change in dopamine neurons may provide a fundamentally new model to assist patients with PD and other neurodegenerative diseases.
